Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Commentary|Videos|December 19, 2023
Key Developments in Obesity Medicine in 2023: An Expert Discussion
Author(s)Sydney Jennings
Angela Fitch, MD, president of the Obesity Medicine Association discusses key pharmaceutical and research developments in obesity medicine in 2023.
Advertisement
"What are the most important pharmaceutical and/or research developments in weight management and obesity medicine in 2023?"
Was a question Patient Care Online asked Angela Fitch, MD, president of the Obesity Medicine Association, in a recent interview. In the video below, Dr Fitch discusses advancements in the nutrient-stimulated hormone category of drug therapy for obesity; the release of
Dr Fitch is also the founder and chief medical officer at knownwell and the former co-director of the Massachusetts General Hospital Weight Center and faculty at Harvard Medical School.
Advertisement
Related to this article
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.
US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
FAQ: What the Endocrine Society’s New Scientific Statement Means for Obesity Treatment
4
Unmet Needs and Mechanisms Behind Newer Agitation Therapies
5